1,608 results on '"Morgillo A"'
Search Results
2. Quantum optical classifier with superexponential speedup
- Author
-
Roncallo, Simone, Morgillo, Angela Rosy, Macchiavello, Chiara, Maccone, Lorenzo, and Lloyd, Seth
- Subjects
Quantum Physics ,Physics - Computational Physics ,Physics - Optics - Abstract
We present a quantum optical pattern recognition method for binary classification tasks. Without direct image reconstruction, it classifies an object in terms of the rate of two-photon coincidences at the output of a Hong-Ou-Mandel interferometer, where both the input and the classifier parameters are encoded into single-photon states. Our method exhibits the same behaviour of a classical neuron of unit depth. Once trained, it shows a constant $\mathcal{O}(1)$ complexity in the number of computational operations and photons required by a single classification. This is a superexponential advantage over a classical neuron (that is at least linear in the image resolution). We provide simulations and analytical comparisons with analogous neural network architectures., Comment: 11 pages, 3 figures
- Published
- 2024
3. Spectral Gap Superposition States
- Author
-
Cugini, Davide, Ghisoni, Francesco, Morgillo, Angela Rosy, and Scala, Francesco
- Subjects
Quantum Physics - Abstract
This work introduces a novel NISQ-friendly procedure for estimating spectral gaps in quantum systems. By leveraging Adiabatic Thermalization, we are able to create the Spectral Gap Superposition state, a newly defined quantum state exhibiting observable fluctuations in time that allow for the accurate estimation of any energy gap. Our method is tested by estimating the energy gap between the ground and the first excited state for the 1D and 2D Ising model, the Hydrogen molecule H2 and Helium molecule He2. Despite limiting our circuit design to have at most 40 Trotter steps, our numerical experiments of both noiseless and noisy devices for the presented systems give relative errors in the order of $10^{-2}$ and $10^{-1}$. Further experiments on the IonQ Aria device lead to spectral gap estimations with a relative error of $10^{-2}$ for a 4-site Ising chain, demonstrating the validity of the procedure for NISQ devices and charting a path towards a new way of calculating energy gaps.
- Published
- 2024
4. Quantum state reconstruction in a noisy environment via deep learning
- Author
-
Morgillo, Angela Rosy, Mangini, Stefano, Piastra, Marco, and Macchiavello, Chiara
- Published
- 2024
- Full Text
- View/download PDF
5. ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC
- Author
-
De Rosa, Caterina, De Rosa, Viviana, Tuccillo, Concetta, Tirino, Virginia, Amato, Luisa, Papaccio, Federica, Ciardiello, Davide, Napolitano, Stefania, Martini, Giulia, Ciardiello, Fortunato, Morgillo, Floriana, Iommelli, Francesca, and Della Corte, Carminia Maria
- Published
- 2024
- Full Text
- View/download PDF
6. Behavioural components and delivery features of early childhood obesity prevention interventions: intervention coding of studies in the TOPCHILD Collaboration systematic review
- Author
-
Brittany J. Johnson, Paul M. Chadwick, Samantha Pryde, Anna Lene Seidler, Kylie E. Hunter, Mason Aberoumand, Jonathan G. Williams, Hei In Lau, Sol Libesman, Jannik Aagerup, Angie Barba, Louise A. Baur, Samantha Morgillo, Lee Sanders, Sarah Taki, Kylie D. Hesketh, Karen Campbell, Alexandra Manson, Alison Hayes, Angela Webster, Charles Wood, Denise A. O’Connor, Karen Matvienko-Sikar, Kristy Robledo, Lisa Askie, Luke Wolfenden, Rachael Taylor, H. Shonna Yin, Vicki Brown, Alexander Fiks, Alison Ventura, Ata Ghaderi, Barry J. Taylor, Cathleen Stough, Christine Helle, Cristina Palacios, Eliana M. Perrin, Elizabeth Reifsnider, Finn Rasmussen, Ian M. Paul, Jennifer S. Savage, Jessica Thomson, Jinan Banna, Junilla Larsen, Kaumudi Joshipura, Ken K. Ong, Levie Karssen, Li Ming Wen, Márcia Vitolo, Margrethe Røed, Maria Bryant, Maribel Campos Rivera, Mary Jo Messito, Natalia Golova, Nina Cecilie Øverby, Rachel Gross, Rajalakshmi Lakshman, Rebecca Byrne, Russell L. Rothman, Sharleen O’Reilly, Stephanie Anzman-Frasca, Vera Verbestel, Claudio Maffeis, Kayla de la Haye, Sarah-Jeanne Salvy, Seema Mihrshahi, Janani Ramachandran, Paola Seffrin Baratto, Rebecca K. Golley, and on behalf of the TOPCHILD Collaboration
- Subjects
Infant feeding ,Diet ,Movement ,Sleep ,Behaviour change techniques ,Intervention components ,Nutritional diseases. Deficiency diseases ,RC620-627 ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background Early childhood obesity prevention interventions that aim to change parent/caregiver practices related to infant (milk) feeding, food provision and parent feeding, movement (including activity, sedentary behaviour) and/or sleep health (i.e. target parental behaviour domains) are diverse and heterogeneously reported. We aimed to 1) systematically characterise the target behaviours, delivery features, and Behaviour Change Techniques (BCTs) used in interventions in the international Transforming Obesity Prevention for CHILDren (TOPCHILD) Collaboration, and 2) explore similarities and differences in BCTs used in interventions by target behaviour domains. Methods Annual systematic searches were performed in MEDLINE, Embase, Cochrane (CENTRAL), CINAHL, PsycINFO, and two clinical trial registries, from inception to February 2023. Trialists from eligible randomised controlled trials of parent-focused, behavioural early obesity prevention interventions shared unpublished intervention materials. Standardised approaches were used to code target behaviours, delivery features and BCTs in both published and unpublished intervention materials. Validation meetings confirmed coding with trialists. Narrative syntheses were performed. Results Thirty-two trials reporting 37 active intervention arms were included. Interventions targeted a range of behaviours. The most frequent combination was targeting all parental behaviour domains (infant [milk] feeding, food provision and parent feeding, movement, sleep health; n[intervention arms] = 15/37). Delivery features varied considerably. Most interventions were delivered by a health professional (n = 26/36), included facilitator training (n = 31/36), and were interactive (n = 28/36). Overall, 49 of 93 unique BCTs were coded to at least one target behaviour domain. The most frequently coded BCTs were: Instruction on how to perform a behaviour (n[intervention arms, separated by domain] = 102), Behavioural practice and rehearsal (n = 85), Information about health consequences (n = 85), Social support (unspecified) (n = 84), and Credible source (n = 77). Similar BCTs were often used for each target behaviour domain. Conclusions Our study provides the most comprehensive description of the behaviour change content of complex interventions targeting early childhood obesity prevention available to date. Our analysis revealed that interventions targeted multiple behaviour domains, with significant variation in delivery features. Despite the diverse range of BCTs coded, five BCTs were consistently identified across domains, though certain BCTs were more prevalent in specific domains. These findings can be used to examine effectiveness of components and inform intervention development and evaluation in future trials. Trial registration PROSPERO registration no. CRD42020177408.
- Published
- 2025
- Full Text
- View/download PDF
7. Quantum State Reconstruction in a Noisy Environment via Deep Learning
- Author
-
Morgillo, Angela Rosy, Mangini, Stefano, Piastra, Marco, and Macchiavello, Chiara
- Subjects
Quantum Physics - Abstract
Quantum noise is currently limiting efficient quantum information processing and computation. In this work, we consider the tasks of reconstructing and classifying quantum states corrupted by the action of an unknown noisy channel using classical feedforward neural networks. By framing reconstruction as a regression problem, we show how such an approach can be used to recover with fidelities exceeding 99% the noiseless density matrices of quantum states of up to three qubits undergoing noisy evolution, and we test its performance with both single-qubit (bit-flip, phase-flip, depolarising, and amplitude damping) and two-qubit quantum channels (correlated amplitude damping). Moreover, we also consider the task of distinguishing between different quantum noisy channels, and show how a neural network-based classifier is able to solve such a classification problem with perfect accuracy.
- Published
- 2023
8. New perspectives on inoperable early-stage lung cancer management: Clinicians, physicists, and biologists unveil strategies and insights
- Author
-
Mauro Buono, Gianluca Russo, Valerio Nardone, Carminia Maria Della Corte, Giovanni Natale, Dino Rubini, Lucia Palumbo, Claudia Scimone, Giovanni Ciani, Ida D'Onofrio, Roberta Grassi, Alfonso Fiorelli, Floriana Morgillo, Alfonso Reginelli, Giancarlo Troncone, and Salvatore Cappabianca
- Subjects
Lung cancer ,Oncology ,Liquid biopsy ,Radiotherapy ,Thoracic surgery ,Medicine - Abstract
This work provides a comprehensive overview of the current landscape of lung cancer, emphasizing the global significance of the disease and the challenges associated with its diagnosis and treatment. The authors highlight the prevalence of lung cancer, with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCC) being the predominant histological subtypes. Advanced-stage diagnosis is common due to the asymptomatic nature of the disease, leading to a systemic treatment approach involving chemotherapy and radiotherapy.The authors discuss the evolution of treatment strategies, with a focus on the emergence of targeted therapies for advanced-stage NSCLC. A panel of predictive biomarkers, both DNA-based (e.g., EGFR, BRAF, KRAS) and RNA-based (e.g., ALK, ROS1, RET, MET), is highlighted as crucial for molecular analysis in diagnostic specimens. While advanced NSCLC patients benefit from targeted therapy, early-stage patients may undergo surgery followed by adjuvant cisplatin-based chemotherapy or stereotactic body radiotherapy (SBRT). The work emphasizes the importance of screening programs for early detection, with a particular focus on the Italian Lung Cancer Screening Network (RISP). RISP aims to recruit high-risk individuals for screening using low-dose computed tomography (LDCT) and implements primary prevention interventions, such as smoking cessation support. The program's objectives include reducing lung cancer mortality, developing a recruitment system for suitable candidates, and integrating radiological, clinical, and molecular data for individual risk profiling. The review also delves into the perspectives of clinicians, physicists, and biologists in the management of lung cancer. Clinicians focus on risk stratification and treatment options, physicists discuss the role of medical physicists in SBRT, and biologists explore precision medicine, biomarkers, and challenges inearly detection.The comparison between surgery and SBRT for early-stage NSCLC patients is discussed, emphasizing the efficacy of SBRT as a non-invasive approach for patients ineligible for surgery. The authors also touch upon ongoing trials addressing the clinical performance of SBRT in comparison to surgery and the challenges posed by preexisting treatment preferences. The physicist's perspective emphasizes the role of medical physicists in lung SBRT, covering aspects from treatment planning to quality assurance. The importance of radiation physics expertise, advanced imaging techniques, image-guided radiation therapy (IGRT), and adaptive radiotherapy is highlighted. Customized models for tumor control and toxicity evaluation, derived from dosimetric analysis, contribute to treatment optimization and patient care. The biologist's viewpoint explores precision medicine in advanced NSCLC treatment, emphasizing the role of somatic alterations as predictive biomarkers. Challenges in early detection are discussed, and the ideal screening tool is proposed to integrate radiological, pathological, and clinical data. Various blood-derived biomarkers and diagnostic assays, such as EarlyCDT-Lung, Nodify XL2, and miRNA-based signatures, are presented as potential tools for early-stage lung cancer detection. In conclusion, the review underscores the multidisciplinary approach required for effective lung cancer management. Advances in early detection, personalized treatment, and the integration of technology and biomarkers offer hope for improving outcomes and reducing the global burden of lung cancer.
- Published
- 2024
- Full Text
- View/download PDF
9. DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer
- Author
-
De Rosa, Caterina, Morgillo, Floriana, Amato, Luisa, Iommelli, Francesca, De Rosa, Viviana, Tirino, Virginia, Papaccio, Federica, Tuccillo, Concetta, Di Guida, Gaetano, D’Angiolella, Domenico Michele, Di Liello, Alessandra, Zappavigna, Silvia, Caraglia, Michele, Gambardella, Antonio, Nardone, Valerio, Ramkumar, Kavya, Wang, Qi, Wang, Jing, De Vita, Ferdinando, Ciardiello, Davide, Martinelli, Erika, Troiani, Teresa, Napolitano, Stefania, Martini, Giulia, Servetto, Alberto, Byers, Lauren Averett, Ciardiello, Fortunato, and Della Corte, Carminia Maria
- Published
- 2025
- Full Text
- View/download PDF
10. Treatment response assessment of acute pyelonephritis: A multi-reader DWI-based MRI approach
- Author
-
Morgillo, Martina, Bernabei, Carlotta, Bianchi, Marco, Vezzani, Valeria, Mastrodicasa, Domenico, Serafini, Francesco Lorenzo, Cocco, Giulio, Corvino, Antonio, Seccia, Barbara, Di Liberato, Lorenzo, Caulo, Massimo, and Delli Pizzi, Andrea
- Published
- 2025
- Full Text
- View/download PDF
11. Supporting parents in the transition to parenthood through wellbeing interventions; An international scoping review
- Author
-
Middleton, Georgia, Matvienko-Sikar, Karen, Briley, Annette, Dutch, Dimity, Morgillo, Samantha, Anderson, Jacqueline, Schranz, Natasha, Margrie, Fiona, Kirby, Rachel, Golley, Rebecca K, and Hunter, Sarah C
- Published
- 2025
- Full Text
- View/download PDF
12. Comparison of kink-band structures and specificities of cell wall polysaccharides in modern and ancient flax fibres
- Author
-
Goudenhooft, Camille, Melelli, Alessia, Durand, Sylvie, Falourd, Xavier, Le-Bot, Lucie, Morgillo, Loren, Gaballah, Sanaa, Cortopassi, Roberta, Quiles, Anita, Shah, Darshil U., Jamme, Frédéric, Beaugrand, Johnny, and Bourmaud, Alain
- Published
- 2024
- Full Text
- View/download PDF
13. A multicriteria approach to quantify contaminant shives in industrial batches of flax fibres
- Author
-
Morgillo, Loren, Durand, Sylvie, Brionne, Lèna, Mourret, Nicolas, d’Arras, Pierre, Abida, Marwa, Beaugrand, Johnny, and Bourmaud, Alain
- Published
- 2024
- Full Text
- View/download PDF
14. Evaluation of a menu box delivery service for Australian long-day care services to improve food provision and child intake: a cluster randomised controlled trial
- Author
-
Shabnam Kashef, Lucinda K Bell, Victoria Brown, Claire Gardner, Dorota Zarnowiecki, Samantha Morgillo, Jennifer C Arguelles, David N Cox, and Rebecca K Golley
- Subjects
Preschool ,Childcare ,Children ,Diet ,Food environments ,Public health ,Public aspects of medicine ,RA1-1270 ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
Abstract Objective: To evaluate the impact of a menu box delivery service tailored to the long-day care (LDC) setting on improving menu compliance with recommendations, children’s diet quality and dietary intake while in care. Design: A cluster randomised controlled trial in LDC centres randomly assigned to an intervention (menu box delivery) or comparison (menu planning training) group. The primary outcome was child food provision and dietary intake. Secondary outcomes include menu compliance and process evaluation, including acceptability, fidelity and menu cost (per child, per day). Setting: South Australian LDC centres. Participants: Eight LDC centres (n 224 children) provided data. Results: No differences were observed in serves/d between intervention and comparison centres, for provision (intervention, 0·9 inter-quartile range (IQR) 0·7–1·2; comparison, 0·8 IQR 0·5–1·3) or consumption (intervention, 0·5 IQR 0·2–0·8; comparison, 0·5 IQR 0·3–0·9) of vegetables. Child food provision and dietary intake were similar across both groups for all food groups (P < 0·05). At follow-up, all intervention centres met menu planning guidelines for vegetables, whereas only one comparison centre met guidelines. Intervention centre directors found the menu box delivery more acceptable than cooks. Cost of the intervention was AUD$2·34 greater than comparison centres (intervention, AUD$4·62 (95 % CI ($4·58, $4·67)); comparison, AUD$2·28 (95 % CI ($2·27, $2·30)) per child, per day). Conclusions: Menu compliance can be improved via a menu delivery service, delivering equivalent impacts on child food provision and dietary intake compared with an online training programme. Further exploration of cooks acceptability and cost is essential before scaling up to implementation.
- Published
- 2023
- Full Text
- View/download PDF
15. Development of an initiatives package to increase children’s vegetable intake in long day care centres using the Multiphase Optimisation Strategy (MOST) randomised factorial experiment
- Author
-
Lucinda K Bell, Samantha Morgillo, Dorota Zarnowiecki, Claire Gardner, Shalem Leemaqz, Jennifer Arguelles, Astrid AM Poelman, Maeva O Cochet-Broch, David N Cox, and Rebecca K Golley
- Subjects
Children ,Vegetable intake ,Multiphase Optimisation Strategy ,Long day care ,Complex interventions ,Public aspects of medicine ,RA1-1270 ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
Abstract Objective: To inform a package of initiatives to increase children’s vegetable intake while in long day care (LDC) by evaluating the independent and combined effects of three initiatives targeting food provision, the mealtime environment and the curriculum. Design: Using the Multiphase Optimisation Strategy (MOST) framework, a 12-week, eight-condition (n 7 intervention, n 1 control) randomised factorial experiment was conducted. Children’s dietary intake data were measured pre- and post-initiative implementation using the weighed plate waste method (1× meal and 2× between-meal snacks). Vegetable intake (g/d) was calculated from vegetable provision and waste. The optimal combination of initiatives was determined using a linear mixed-effects model comparing between-group vegetable intake at follow-up, while considering initiative fidelity and acceptability. Setting: LDC centres in metropolitan Adelaide, South Australia. Participants: 32 centres, 276 staff and 1039 children aged 2–5 years. Results: There were no statistically significant differences between any of the intervention groups and the control group for vegetable intake (all P > 0·05). The curriculum with mealtime environment group consumed 26·7 g more vegetables/child/day than control (ratio of geometric mean 3·29 (95 % CI 0·96, 11·27), P = 0·06). Completion rates for the curriculum (> 93 %) and mealtime environment (61 %) initiatives were high, and acceptability was good (4/5 would recommend), compared with the food provision initiative (0–50 % completed the menu assessment, 3/5 would recommend). Conclusion: A programme targeting the curriculum and mealtime environment in LDC may be useful to increase children’s vegetable intake. Determining the effectiveness of this optimised package in a randomised controlled trial is required, as per the evaluation phase of the MOST framework.
- Published
- 2023
- Full Text
- View/download PDF
16. Revealing degradation mechanisms of archaeological flax textiles through the evolution of fibres’ parietal polymers by synchrotron deep-UV fluorescence
- Author
-
Melelli, Alessia, Goudenhooft, Camille, Durand, Sylvie, Quiles, Anita, Cortopassi, Roberta, Morgillo, Loren, Magueresse, Anthony, Beaugrand, Johnny, Jamme, Frédéric, and Bourmaud, Alain
- Published
- 2024
- Full Text
- View/download PDF
17. Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)
- Author
-
Pizzutilo, E.G., Agostara, A.G., Oresti, S., Signorelli, D., Stabile, S., Lauricella, C., Motta, V., Amatu, A., Ruggieri, L., Brambilla, M., Occhipinti, M., Proto, C., Giusti, R., Filetti, M., Genova, C., Barletta, G., Gelsomino, F., Bennati, C., Siringo, M., Di Fazio, G.R., Russano, M., Montrone, M., Gariazzo, E., Roca, E., Bordi, P., Delmonte, A., Scimone, A., Belluomini, L., Mazzoni, F., Carta, A., Pelizzari, G., Viscardi, G., Morgillo, F., Gelibter, A., Gori, S., Berardi, R., Cortinovis, D., Ardizzoni, A., Veronese, S.M., Sartore-Bianchi, A., Giannetta, L.G., Cerea, G., and Siena, S.
- Published
- 2024
- Full Text
- View/download PDF
18. Vedolizumab as Rescue Therapy in Carboplatin-Gemcitabine-Induced Triggered Acute Severe Ulcerative Colitis Flare-Up
- Author
-
Raffaele Pellegrino, Morena Fasano, Floriana Morgillo, Giovanna Palladino, Isabella Vassallo, Mario Pirozzi, Giuseppe Imperio, Salvatore Auletta, Andrea Ventura, Iacopo Panarese, Alessandro Federico, and Antonietta Gerarda Gravina
- Subjects
ulcerative colitis ,inflammatory bowel disease ,acute severe ulcerative colitis ,chemotherapy ,lung cancer ,Medicine ,Diseases of the digestive system. Gastroenterology ,RC799-869 - Abstract
Approximately 20% of patients with ulcerative colitis (UC) develop acute severe UC (ASUC), for which intravenous systemic steroid therapy and possibly infliximab-based rescue therapy are generally imposed. However, there are no significant guideline recommendations on ASUC regarding vedolizumab as an alternative in this setting. A case report was presented where a patient with steroid-dependent UC developed ASUC induced by second-line chemotherapy. Treatment with intravenous methylprednisolone was imposed, but there was no reduction in bowel movements in the days following admission. Rescue therapy with infliximab was contraindicated because of the oncologic history. Surgical consultation, contraindicated colectomy, and administration of vedolizumab 300 mg were initiated. After infusion with vedolizumab, there was a significant reduction in bowel movements starting the day after infusion until normalisation of bowel movements within three days and the concomitant normalisation of inflammatory indices. The patient is currently in clinical remission, on therapy with vedolizumab 108 mg subcutaneously every two weeks, and is in oncologic follow-up for pulmonary neoplasm. This case highlights the novel potential of vedolizumab as a possible rescue therapy in ASUC, especially in special populations, where it may offer a better safety profile. Although cyclosporine and infliximab still represent the mainstays of salvage therapy for steroid-refractory ASUC, new therapeutic agents may also be effective, such as vedolizumab, ustekinumab, and anti-Janus kinase agents.
- Published
- 2023
- Full Text
- View/download PDF
19. Targeting EphA2 and DDR signaling can overcome the BRAF and MEK inhibitors acquired resistance in melanoma cell lines
- Author
-
Belli, Valentina, Napolitano, Stefania, De Falco, Vincenzo, Suarato, Gabriella, Perrone, Alessandra, Guerrera, Luigi Pio, Martini, Giulia, Della Corte, Carminia Maria, Martinelli, Erika, Morgillo, Floriana, Turano, Mimmo, Furia, Maria, Argenziano, Giuseppe, Ciardiello, Davide, Ciardiello, Fortunato, and Troiani, Teresa
- Published
- 2023
- Full Text
- View/download PDF
20. Exploring the DNA2-PNA heterotriplex formation in targeting the Bcl-2 gene promoter: A structural insight by physico-chemical and microsecond-scale MD investigation
- Author
-
Falanga, Andrea P., Lupia, Antonio, Tripodi, Lorella, Morgillo, Carmine M., Moraca, Federica, Roviello, Giovanni N., Catalanotti, Bruno, Amato, Jussara, Pastore, Lucio, Cerullo, Vincenzo, D'Errico, Stefano, Piccialli, Gennaro, Oliviero, Giorgia, and Borbone, Nicola
- Published
- 2024
- Full Text
- View/download PDF
21. Elucidating links between the mechanical performance of flax fibres and their structural defects
- Author
-
Morgillo, Loren, Brionne, Lèna, Melelli, Alessia, Ouagne, Pierre, Scheel, Mario, Weitkamp, Timm, Shah, Darshil U., Abida, Marwa, Beaugrand, Johnny, and Bourmaud, Alain
- Published
- 2023
- Full Text
- View/download PDF
22. Evaluation of a long day care intervention targeting the mealtime environment and curriculum to increase children’s vegetable intake: a cluster randomised controlled trial using the multiphase optimisation strategy framework
- Author
-
Samantha Morgillo, Lucinda K Bell, Claire Gardner, Shabnam Kashef, Karen Stafford, Dorota Zarnowiecki, Astrid AM Poelman, Maeva O Cochet-Broch, Brittany J Johnson, Aarti Gulyani, David N Cox, and Rebecca K Golley
- Subjects
Children ,Vegetable intake ,Long day care ,Multiphase optimisation strategy ,Randomised controlled trial ,Public aspects of medicine ,RA1-1270 ,Nutritional diseases. Deficiency diseases ,RC620-627 - Abstract
Abstract Objective: To determine the reach, adoption, implementation and effectiveness of an intervention to increase children’s vegetable intake in long day care (LDC). Design: A 12-week pragmatic cluster randomised controlled trial, informed by the multiphase optimisation strategy (MOST), targeting the mealtime environment and curriculum. Children’s vegetable intake and variety was measured at follow-up using a modified Short Food Survey for early childhood education and care and analysed using a two-part mixed model for non-vegetable and vegetable consumers. Outcome measures were based on the RE-AIM framework. Setting: Australian LDC centres. Participants: Thirty-nine centres, 120 educators and 719 children at follow-up. Results: There was no difference between intervention and waitlist control groups in the likelihood of consuming any vegetables when compared with non-vegetable consumers for intake (OR = 0·70, (95 % CI 0·34–1·43), P = 0·32) or variety (OR = 0·73 (95 % CI 0·40–1·32), P = 0·29). Among vegetable consumers (n 652), there was no difference between groups in vegetable variety (exp(b): 1·07 (95 % CI:0·88–1·32, P = 0·49) or vegetable intake (exp(b): 1·06 (95 % CI: 0·78, 1·43)), P = 0·71) with an average of 1·51 (95 % CI 1·20–1·82) and 1·40 (95 % CI 1·08–1·72) serves of vegetables per day in the intervention and control group, respectively. Intervention educators reported higher skills for promoting vegetables at mealtimes, and knowledge and skills for teaching the curriculum, than control (all P < 0·001). Intervention fidelity was moderate (n 16/20 and n 15/16 centres used the Mealtime environment and Curriculum, respectively) with good acceptability among educators. The intervention reached 307/8556 centres nationally and was adopted by 22 % eligible centres. Conclusions: The pragmatic self-delivered online intervention positively impacted educator’s knowledge and skills and was considered acceptable and feasible. Intervention adaptations, using the MOST cyclic approach, could improve intervention impact on children’ vegetable intake.
- Published
- 2024
- Full Text
- View/download PDF
23. A world-first food service satisfaction questionnaire for use with family members of nursing home residents: expanding the toolkit of valid and reliable aged care food service satisfaction questionnaires
- Author
-
Alison Yaxley, Morgan Pankhurst, Stephanie Morgillo, and Michelle Miller
- Subjects
Food service satisfaction ,Nursing home ,Residential aged care ,Psychometric ,Family ,Internal medicine ,RC31-1245 - Abstract
Objectives: This study aimed to develop a valid and reliable food service satisfaction questionnaire for use by family members of residents in nursing homes. Design: Questionnaire development and validation study conducted using COSMIN® benchmarks for excellence. Setting: Nursing homes. Participants: Family members of residents in nursing homes. Measurements: Content validity was established based on a review of the literature, qualitative interviews with family members (n = 9) and expert review (n = 10). Face validity was established in pilot testing with family members (n = 5). A 40-item questionnaire was developed for psychometric testing. Data from 414 family members was used to establish construct validity (Principal Components Analysis), with data from 101 of those family members used to evaluate reliability (internal consistency (Cronbach’s alpha [α]) and temporal stability [weighted Kappa]). Results: A two factor 24-item scale resulted, with excellent internal consistency (factor one: 11 items related to food and meals (α = 0.960); factor two: 13 items related to the mealtime experience (α = 0.907)). Temporal stability was moderate to near perfect (weighted Kappa: 0.461−0.875; p
- Published
- 2024
- Full Text
- View/download PDF
24. Collecting clinical data during an emergency: quality of life in primary biliary cholangitis during the COVID-19 pandemic
- Author
-
Marco Delle Monache, Marco Carli, Annarita Vestri, Lorenzo Nosotti, Teresa Morgillo, and Michele Delle Monache
- Subjects
Primary biliary cholangitis ,quality of life ,COVID-19 ,social networks ,Medicine - Abstract
Background. Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease. As an infrequent disease, a Facebook group was created for patients to share experiences and problems. In fact, during the COVID-19 pandemic, patient analysis could only be done through remote connection systems. Therefore, to analyze patients' quality of life (QoL), we exploited social networks and online data collection platforms. Objectives. A survey was carried out to evaluate the QoL of patients with PBC during the COVID-19 pandemic. Materials and Methods. A Facebook group was used for patient enrolment. Age, sex, diagnosis, years since diagnosis, associated diseases, histological stage of the disease, value of elastography, and current therapy were collected. PBC 40 online questionnaire was submitted to patients to assess their QoL. Results. 78 patients participated in the study: 75 females, and 3 males, the mean (±SD) age was 46.4±11.5. The main diagnoses were PBC in 66 patients and overlapping syndrome PBC + autoimmune hepatitis in 10. Histology was available in 45 patients, of whom 34 were stages 1-2 and 11 stages 3-4. The main therapy was ursodeoxycholic acid in 56 pts. The questionnaire is divided into 6 domains, covering fatigue, emotional, social, and cognitive functions, general symptoms, and itching. The mean and standard deviation of the scores were computed. Interpretation of the results obtained by applying a quantitative scale showed no impairment for social, mild impairment for general symptoms, itching, cognitive and emotional function, and moderate impairment for fatigue. No correlation was found between scores and disease duration. Conclusions. This study demonstrates that online questionnaires are a viable substitute for paper questionnaires and that data collected from online surveys on Facebook can have scientific relevance; PBC had the greatest impact on QoL on fatigue and the least on social aspects.
- Published
- 2023
- Full Text
- View/download PDF
25. PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer
- Author
-
Caterina De Rosa, Francesca Iommelli, Viviana De Rosa, Giuseppe Ercolano, Federica Sodano, Concetta Tuccillo, Luisa Amato, Virginia Tirino, Annalisa Ariano, Flora Cimmino, Gaetano di Guida, Gennaro Filosa, Alessandra di Liello, Davide Ciardiello, Erika Martinelli, Teresa Troiani, Stefania Napolitano, Giulia Martini, Fortunato Ciardiello, Federica Papaccio, Floriana Morgillo, and Carminia Maria Della Corte
- Subjects
PBMC ,cGAS-STING ,biomarker ,Biology (General) ,QH301-705.5 - Abstract
Background: Lung cancer (LC), including both non-small (NSCLC) and small (SCLC) subtypes, is currently treated with a combination of chemo- and immunotherapy. However, predictive biomarkers to identify high-risk patients are needed. Here, we explore the role of peripheral blood mononuclear cells (PBMCs) as a tool for novel biomarkers searching. Methods: We analyzed the expression of the cGAS-STING pathway, a key DNA sensor that activates during chemotherapy, in PBMCs from LC patients divided into best responders (BR), responders (R) and non-responders (NR). The PBMCs were whole exome sequenced (WES). Results: PBMCs from BR and R patients of LC cohorts showed the highest levels of STING (p < 0.0001) and CXCL10 (p < 0.0001). From WES, each subject had at least 1 germline/somatic alteration in a DDR gene and the presence of more DDR gene mutations correlated with clinical responses, suggesting novel biomarker implications. Thus, we tested the effect of the pharmacological DDR inhibitor (DDRi) in PBMCs and in three-dimensional spheroid co-culture of PBMCs and LC cell lines; we found that DDRi strongly increased cGAS-STING expression and tumor infiltration ability of immune cells in NR and R patients. Furthermore, we performed FACS analysis of PBMCs derived from LC patients from the BR, R and NR cohorts and we found that cytotoxic T cell subpopulations displayed the highest STING expression. Conclusions: cGAS-STING signaling activation in PBMCs may be a novel potential predictive biomarker for the response to immunotherapy and high levels are correlated with a better response to treatment along with an overall increased antitumor immune injury.
- Published
- 2024
- Full Text
- View/download PDF
26. Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC
- Author
-
Carminia Maria Della Corte, Vincenza Ciaramella, Kavya Ramkumar, Giovanni Vicidomini, Alfonso Fiorelli, Valerio Nardone, Salvatore Cappabianca, Immacolata Cozzolino, Federica Zito Marino, Gaetano Di Guida, Qi Wang, Robert Cardnell, Carl Michael Gay, Davide Ciardiello, Erika Martinelli, Teresa Troiani, Giulia Martini, Stefania Napolitano, Jing Wang, Lauren Averett Byers, Fortunato Ciardiello, and Floriana Morgillo
- Subjects
Ido-1 ,Checkpoint inhibitor ,Resistance ,EMT ,Medicine - Abstract
Abstract Background Despite the recent progress in the treatment and outcome of Non Small Cell Lung Cancer (NSCLC), immunotherapy has still significant limitations reporting a significant proportion of patients not benefiting from therapy, even in patients with high PD-L1 expression. We have previously demonstrated that the combined inhibition of MEK and PD-L1 in NSCLC patients derived three dimensional cultures exerted significant synergistic effect in terms of immune-dependent cancer cell death. However, subsequent experiments analyzing the expression of Indoleamine 2,3-dioxygenase-1 (Ido-1) gene expression demonstrated that Ido-1 resulted unaffected by the MEK inhibition and even increased after the combined inhibition of MEK and PD-L1 thus representing a potential escape mechanism to this combination. Methods We analyzed transcriptomic profile of NSCLC lung adenocarcinoma cohort of TCGA (The Cancer Genome Atlas), stratifying tumors based on EMT (Epithelial mesenchymal Transition) score; in parallel, we investigated the activation of Ido-1 pathway and modulation of immune cytokines productions both in NSCLC cells lines, in peripheral blood mononuclear cells (PBMCs) and in ex-vivo NSCLC spheroids induced by triple inhibition with an anti-PD-L1 monoclonal antibody, the MEK inhibitor and the Ido-1 inhibitor. Results In NSCLC lung adenocarcinoma patient cohort (from TCGA) Ido-1 gene expression was significantly higher in samples classified as mesenchymal according EMT score. Similarly, on a selected panel of NSCLC cell lines higher expression of MEK and Ido-1 related genes was detected in cells with mesenchymal phenotype according EMT score, thus suggesting a potential correlation of co-activation of these two pathways in the context of EMT, with cancer cells sustaining an immune-suppressive microenvironment. While exerting an antitumor activity, the dual blockade of MEK and PD-L1 enhances the secretion of pro-inflammatory cytokines (IFNγ, TNFα, IL-12 and IL-6) and, consequently, the expression of new immune checkpoints such as Ido-1. The triple inhibition with an anti-PD-L1 monoclonal antibody, the MEK inhibitor and the Ido-1 inhibitor demonstrated significant antiproliferative and proapoptotic activity on ex-vivo NSCLC samples; at the same time the triple combination kept increased the levels of pro-inflammatory cytokines produced by both PBMCs and tumor spheroids in order to sustain the immune response and simultaneously decreased the expression of other checkpoint (such as CTLA-4, Ido-1 and TIM-3) thus promoting an immune-reactive and inflamed micro-environment. Conclusions We show that Ido-1 activation is a possible escape mechanism to immune-mediated cell death induced by combination of PD-L1 and MEK inhibitors: also, we show that triple combination of anti-PD-L1, anti-MEK and anti-Ido-1 drugs may overcome this negative feedback and restore anti-tumor immune response in NSCLC patients’ derived three dimensional cultures.
- Published
- 2022
- Full Text
- View/download PDF
27. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
- Author
-
Viscardi, Giuseppe, Tralongo, Antonino C., Massari, Francesco, Lambertini, Matteo, Mollica, Veronica, Rizzo, Alessandro, Comito, Francesca, Di Liello, Raimondo, Alfieri, Salvatore, Imbimbo, Martina, Della Corte, Carminia M., Morgillo, Floriana, Simeon, Vittorio, Lo Russo, Giuseppe, Proto, Claudia, Prelaj, Arsela, De Toma, Alessandro, Galli, Giulia, Signorelli, Diego, Ciardiello, Fortunato, Remon, Jordi, Chaput, Nathalie, Besse, Benjamin, de Braud, Filippo, Garassino, Marina C., Torri, Valter, Cinquini, Michela, and Ferrara, Roberto
- Published
- 2022
- Full Text
- View/download PDF
28. Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial
- Author
-
Piccirillo, Maria Carmela, Bonanno, Laura, Garassino, Marina Chiara, Esposito, Giovanna, Dazzi, Claudio, Cavanna, Luigi, Burgio, Marco Angelo, Rosetti, Francesco, Rizzato, Simona, Morgillo, Floriana, Cinieri, Saverio, Veccia, Antonello, Papi, Maximilan, Tonini, Giuseppe, Gebbia, Vittorio, Ricciardi, Serena, Pozzessere, Daniele, Ferro, Alessandra, Proto, Claudia, Costanzo, Raffaele, D’Arcangelo, Manolo, Proietto, Manuela, Gargiulo, Piera, Di Liello, Raimondo, Arenare, Laura, De Marinis, Filippo, Crinò, Lucio, Ciardiello, Fortunato, Normanno, Nicola, Gallo, Ciro, Perrone, Francesco, Gridelli, Cesare, and Morabito, Alessandro
- Published
- 2022
- Full Text
- View/download PDF
29. Impact of a cardio‐oncology unit on prevention of cardiovascular events in cancer patients
- Author
-
Alessandra Cuomo, Valentina Mercurio, Gilda Varricchi, Maria Rosaria Galdiero, Francesca Wanda Rossi, Antonio Carannante, Grazia Arpino, Luigi Formisano, Roberto Bianco, Chiara Carlomagno, Carmine De Angelis, Mario Giuliano, Elide Matano, Marco Picardi, Domenico Salvatore, Ferdinando De Vita, Erika Martinelli, Carminia Maria Della Corte, Floriana Morgillo, Michele Orditura, Stefania Napolitano, Teresa Troiani, and Carlo G. Tocchetti
- Subjects
Cardio‐oncology ,Cardiotoxicity ,Cardiovascular risk factors ,Heart failure ,Cancer ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Aims As the world population grows older, the co‐existence of cancer and cardiovascular comorbidities becomes more common, complicating management of these patients. Here, we describe the impact of a large Cardio‐Oncology unit in Southern Italy, characterizing different types of patients and discussing challenges in therapeutic management of cardiovascular complications. Methods and results We enrolled 231 consecutive patients referred to our Cardio‐Oncology unit from January 2015 to February 2020. Three different types were identified, according to their chemotherapeutic statuses at first visit. Type 1 included patients naïve for oncological treatments, Type 2 patients already being treated with oncological treatments, and Type 3 patients who had already completed cancer treatments. Type 2 patients presented the highest incidence of cardiovascular events (46.2% vs. 12.3% in Type 1 and 17.9% in Type 3) and withdrawals from oncological treatments (5.1% vs. none in Type 1) during the observation period. Type 2 patients presented significantly worse 48 month‐survival (32.1% vs. 16.7% in Type 1 and 17.9% in Type 3), and this was more evident when in the three groups we focused on patients with uncontrolled cardiovascular risk factors or overt cardiovascular disease at the first cardiologic assessment. Nevertheless, these patients showed the greatest benefit from our cardiovascular assessments, as witnessed by a small, but significant improvement in ejection fraction during follow‐up (Type 2b: from 50 [20; 67] to 55 [35; 65]; P = 0.04). Conclusions Patients who start oncological protocols without an accurate baseline cardiovascular evaluation are at major risk of developing cardiac complications due to antineoplastic treatments.
- Published
- 2022
- Full Text
- View/download PDF
30. Immunotherapy for head and neck cancer: Present and future
- Author
-
Fasano, Morena, Corte, Carminia Maria Della, Liello, Raimondo Di, Viscardi, Giuseppe, Sparano, Francesca, Iacovino, Maria Lucia, Paragliola, Fernando, Piccolo, Antonio, Napolitano, Stefania, Martini, Giulia, Morgillo, Floriana, Cappabianca, Salvatore, and Ciardiello, Fortunato
- Published
- 2022
- Full Text
- View/download PDF
31. Behavioural components and delivery features of early childhood obesity prevention interventions: intervention coding of studies in the TOPCHILD Collaboration systematic review.
- Author
-
Johnson, Brittany J., Chadwick, Paul M., Pryde, Samantha, Seidler, Anna Lene, Hunter, Kylie E., Aberoumand, Mason, Williams, Jonathan G., Lau, Hei In, Libesman, Sol, Aagerup, Jannik, Barba, Angie, Baur, Louise A., Morgillo, Samantha, Sanders, Lee, Taki, Sarah, Hesketh, Kylie D., Campbell, Karen, Manson, Alexandra, Hayes, Alison, and Webster, Angela
- Abstract
Background: Early childhood obesity prevention interventions that aim to change parent/caregiver practices related to infant (milk) feeding, food provision and parent feeding, movement (including activity, sedentary behaviour) and/or sleep health (i.e. target parental behaviour domains) are diverse and heterogeneously reported. We aimed to 1) systematically characterise the target behaviours, delivery features, and Behaviour Change Techniques (BCTs) used in interventions in the international Transforming Obesity Prevention for CHILDren (TOPCHILD) Collaboration, and 2) explore similarities and differences in BCTs used in interventions by target behaviour domains. Methods: Annual systematic searches were performed in MEDLINE, Embase, Cochrane (CENTRAL), CINAHL, PsycINFO, and two clinical trial registries, from inception to February 2023. Trialists from eligible randomised controlled trials of parent-focused, behavioural early obesity prevention interventions shared unpublished intervention materials. Standardised approaches were used to code target behaviours, delivery features and BCTs in both published and unpublished intervention materials. Validation meetings confirmed coding with trialists. Narrative syntheses were performed. Results: Thirty-two trials reporting 37 active intervention arms were included. Interventions targeted a range of behaviours. The most frequent combination was targeting all parental behaviour domains (infant [milk] feeding, food provision and parent feeding, movement, sleep health; n[intervention arms] = 15/37). Delivery features varied considerably. Most interventions were delivered by a health professional (n = 26/36), included facilitator training (n = 31/36), and were interactive (n = 28/36). Overall, 49 of 93 unique BCTs were coded to at least one target behaviour domain. The most frequently coded BCTs were: Instruction on how to perform a behaviour (n[intervention arms, separated by domain] = 102), Behavioural practice and rehearsal (n = 85), Information about health consequences (n = 85), Social support (unspecified) (n = 84), and Credible source (n = 77). Similar BCTs were often used for each target behaviour domain. Conclusions: Our study provides the most comprehensive description of the behaviour change content of complex interventions targeting early childhood obesity prevention available to date. Our analysis revealed that interventions targeted multiple behaviour domains, with significant variation in delivery features. Despite the diverse range of BCTs coded, five BCTs were consistently identified across domains, though certain BCTs were more prevalent in specific domains. These findings can be used to examine effectiveness of components and inform intervention development and evaluation in future trials. Trial registration: PROSPERO registration no. CRD42020177408. [ABSTRACT FROM AUTHOR]
- Published
- 2025
- Full Text
- View/download PDF
32. Diagnostic Challenges in the Pathological Approach to Pleural Mesothelioma.
- Author
-
Lucà, Stefano, Pignata, Giovanna, Cioce, Alessandro, Salzillo, Cecilia, De Cecio, Rossella, Ferrara, Gerardo, Della Corte, Carminia Maria, Morgillo, Floriana, Fiorelli, Alfonso, Montella, Marco, and Franco, Renato
- Abstract
Simple Summary: Malignant pleural mesothelioma poses a significant diagnostic challenge for pathologists, requiring a comprehensive multidisciplinary approach. Diagnosis relies on morphological, immunohistochemical, and sometimes molecular assessments, integrated with clinical and radiological findings. The first diagnostic challenge is distinguishing MPM from metastatic pleural lesions or benign mesothelial proliferations. Immunohistochemical markers such as podoplanin, WT1, calretinin, and HEG1 are pivotal, though none is entirely specific. In the same way, BAP1 and MTAP provide enhanced sensitivity and specificity for differentiating malignant from benign conditions and, in more complex cases, molecular tests can detect valuable genetic alterations. The International Mesothelioma Interest Group regularly updates its guidelines to optimize and refine diagnostic processes. The aim is to enhance diagnostic precision and improve the clinical management of MPM. Malignant pleural mesothelioma (MPM) still represents a complex diagnostic challenge for pathologists in routine practice. This diagnosis requires a multidisciplinary approach, and pathological evaluation is mandatory. The histopathological diagnosis is stepwise and should be based on morphological and immunohistochemical assessment, sometimes associated with molecular tests, and supported by clinical and radiological findings. A correct morphological approach aims to exclude pleural metastasis or benign mesothelial proliferations, which are the main differential diagnoses. While certain histological features are diagnostic of MPM, others are highly suggestive but not definitive. Immunohistochemistry plays a pivotal role, with a panel of both traditional and newer markers being used to assess mesothelial differentiation and to differentiate malignant from benign proliferations. In more challenging cases, molecular tests, such as fluorescent in situ hybridization (FISH) to detect CDKN2A deletion, can be helpful in distinguishing malignant from benign pleural lesions. This review summarizes the key morphological, immunohistochemical, and molecular features that should be considered when pleural biopsy samples are examined, with the aim of improving diagnostic accuracy in this complex area. [ABSTRACT FROM AUTHOR]
- Published
- 2025
- Full Text
- View/download PDF
33. Discovery of N-substituted-2-oxoindolin benzoylhydrazines as c-MET/SMO modulators in EGFRi-resistant non-small cell lung cancer.
- Author
-
Tomassi, Stefano, Natale, Benito, Roggia, Michele, Amato, Luisa, De Rosa, Caterina, Della Corte, Carminia Maria, Baglini, Emma, Amendola, Giorgio, Messere, Anna, Di Maro, Salvatore, Barresi, Elisabetta, Da Settimo, Federico, Trincavelli, Maria Letizia, Ciardiello, Fortunato, Taliani, Sabrina, Morgillo, Floriana, and Cosconati, Sandro
- Published
- 2025
- Full Text
- View/download PDF
34. Combined Therapeutic Strategies Based on the Inhibition of Non-Oncogene Addiction to Improve Tumor Response in EGFR- and KRAS-Mutant Non-Small-Cell Lung Cancer.
- Author
-
Amato, Luisa, Omodei, Daniela, De Rosa, Caterina, Ariano, Annalisa, Capaldo, Sara, Tufano, Camilla Carmela, Buono, Rossella, Terlizzi, Cristina, Nardelli, Anna, Del Vecchio, Vitale, Palumbo, Rosanna, Tuccillo, Concetta, Morgillo, Floriana, Papaccio, Federica, Tirino, Virginia, Iommelli, Francesca, Della Corte, Carminia Maria, and De Rosa, Viviana
- Subjects
COMBINATION drug therapy ,CELL migration inhibition ,RESEARCH funding ,PROTEIN-tyrosine kinase inhibitors ,CELL proliferation ,CELLULAR signal transduction ,TUMOR markers ,CELL lines ,GENE expression ,ENERGY metabolism ,DNA damage ,OXIDOREDUCTASES ,CELL death ,ONCOGENES ,LUNG cancer ,GENETIC mutation ,PHOSPHOTRANSFERASES ,COMPARATIVE studies ,EPIDERMAL growth factor receptors - Abstract
Simple Summary: Oncogene-driven non-small-cell lung cancer (NSCLC) is typically treated with targeted therapies to inhibit oncogene downstream signaling pathways and reduce tumor survival. The most common subtypes, EGFR and KRAS mutations, are amenable to these therapies; however, resistance often develops, leading to oncogene-independent metastases. This study explores non-oncogene addiction (NOA) as a novel strategy, targeting essential genes like ATR, which is involved in DNA damage response, and pyruvate dehydrogenase kinases (PDKs), which play a role in energy metabolism. Experiments were conducted using sensitive PC9 and the corresponding osimertinib-resistant cells (PC9/OR), namely EGFR-mutant H1975 and KRAS-mutant A549 cells treated with TKIs, alongside ATR and DCA inhibitors. The results indicated that combining these approaches could enhance efficacy compared to TKIs alone, suggesting a tailored strategy based on tumor subtype. This research underscores the potential of new therapeutic targets to improve treatment outcomes in patients with NSCLC compared to traditional TKI therapies. Background: Oncogene-driven NSCLC is usually treated with targeted therapies using tyrosine kinase inhibitors (TKIs) to inhibit oncogene downstream signaling pathways, affecting tumor survival and proliferation. EGFR- and KRAS-mutant NSCLCs are the most represented subtypes, and they are treated in clinical practice with oncogene-targeting drugs in the first and second line, respectively. Unfortunately, the development of oncogene-independent resistant clones limits TKI efficacy. Here, we used non-oncogene addiction (NOA) as an innovative therapeutic strategy to target other essential proteins that support changes in tumor phenotype. Specifically, we tested, for the first time, a combination of inhibitors, namely ATR, involved in DNA damage response, and pyruvate dehydrogenase kinases (PDKs), involved in energy metabolism. Methods: Sensitive PC9 and the corresponding EGFR-TKI-resistant PC9/OR, EGFR-mutant H1975, and KRAS-mutant A549 NSCLC cells, were treated with TKIs (osimertinib and selumetinib, respectively). In parallel, cells were exposed to two combination regimens: one using the TKI with an ATR inhibitor and the other one combining the two selected NOA inhibitors (ATR inhibitor, M4344; and PDK inhibitor, DCA). Results: The effect of these two combined approaches, compared to TKI alone, produced similar results in terms of cell proliferation, cell death, and migration. Thus, depending on tumor biology, selecting between the proposed therapeutic strategies will be different, to maximize tumor response. Conclusions: The major translational relevance of this study is to exploit new targets for the development of innovative and improved therapeutic strategies with NOA drugs, over combinations including target genes within the oncogene pathway, to overcome resistance to TKI therapies in patients with NSCLC who are oncogene-addicted. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry
- Author
-
Whisenant, Jennifer G., Baena, Javier, Cortellini, Alessio, Huang, Li-Ching, Lo Russo, Giuseppe, Porcu, Luca, Wong, Selina K., Bestvina, Christine M., Hellmann, Matthew D., Roca, Elisa, Rizvi, Hira, Monnet, Isabelle, Boudjemaa, Amel, Rogado, Jacobo, Pasello, Giulia, Leighl, Natasha B., Arrieta, Oscar, Aujayeb, Avinash, Batra, Ullas, Azzam, Ahmed Y., Unk, Mojca, Azab, Mohammed A., Zhumagaliyeva, Ardak N., Gomez-Martin, Carlos, Blaquier, Juan B., Geraedts, Erica, Mountzios, Giannis, Serrano-Montero, Gloria, Reinmuth, Niels, Coate, Linda, Marmarelis, Melina, Presley, Carolyn J., Hirsch, Fred R., Garrido, Pilar, Khan, Hina, Baggi, Alice, Mascaux, Celine, Halmos, Balazs, Ceresoli, Giovanni L., Fidler, Mary J., Scotti, Vieri, Métivier, Anne-Cécile, Falchero, Lionel, Felip, Enriqueta, Genova, Carlo, Mazieres, Julien, Tapan, Umit, Brahmer, Julie, Bria, Emilio, Puri, Sonam, Popat, Sanjay, Reckamp, Karen L., Morgillo, Floriana, Nadal, Ernest, Mazzoni, Francesca, Agustoni, Francesco, Bar, Jair, Grosso, Federica, Avrillon, Virginie, Patel, Jyoti D., Gomes, Fabio, Ibrahim, Ehab, Trama, Annalisa, Bettini, Anna C., Barlesi, Fabrice, Dingemans, Anne-Marie, Wakelee, Heather, Peters, Solange, Horn, Leora, Garassino, Marina Chiara, and Torri, Valter
- Published
- 2022
- Full Text
- View/download PDF
36. Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario
- Author
-
Cantini, L., Mentrasti, G., Russo, G.L., Signorelli, D., Pasello, G., Rijavec, E., Russano, M., Antonuzzo, L., Rocco, D., Giusti, R., Adamo, V., Genova, C., Tuzi, A., Morabito, A., Gori, S., Verde, N. La, Chiari, R., Cortellini, A., Cognigni, V., Pecci, F., Indini, A., De Toma, A., Zattarin, E., Oresti, S., Pizzutilo, E.G., Frega, S., Erbetta, E., Galletti, A., Citarella, F., Fancelli, S., Caliman, E., Della Gravara, L., Malapelle, U., Filetti, M., Piras, M., Toscano, G., Zullo, L., De Tursi, M., Di Marino, P., D’Emilio, V., Cona, M.S., Guida, A., Caglio, A., Salerno, F., Spinelli, G., Bennati, C., Morgillo, F., Russo, A., Dellepiane, C., Vallini, I., Sforza, V., Inno, A., Rastelli, F., Tassi, V., Nicolardi, L., Pensieri, V., Emili, R., Roca, E., Migliore, A., Galassi, T., Rocchi, M. L. Bruno, and Berardi, R.
- Published
- 2022
- Full Text
- View/download PDF
37. Frailty as a predictor of mortality in COVID-19 patients receiving CPAP for respiratory insufficiency
- Author
-
Damanti, Sarah, Ramirez, Giuseppe Alvise, Bozzolo, Enrica Paola, Da Prat, Valentina, Di Lucca, Giuseppe, Di Terlizzi, Gaetano, Marinosci, Alessandro, Scotti, Raffaella, Strada, Silvia, Scarpellini, Paolo, Castiglioni, Barbara, Oltolini, Chiara, Ripa, Marco, Din, Chiara Tassan, Centurioni, Clarissa Elisabeth, Di Scala, Flavia, Gobbi, Agnese, Alba, Ada Carla, Casiraghi, Giuseppina Maria, Morgillo, Anna, and Tresoldi, Moreno
- Published
- 2022
- Full Text
- View/download PDF
38. Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial
- Author
-
Carminia Maria Della Corte, Morena Fasano, Vincenza Ciaramella, Flora Cimmino, Robert Cardnell, Carl M. Gay, Kavya Ramkumar, Lixia Diao, Raimondo Di Liello, Giuseppe Viscardi, Vincenzo Famiglietti, Davide Ciardiello, Giulia Martini, Stefania Napolitano, Concetta Tuccillo, Teresa Troiani, Erika Martinelli, Jing Wang, Lauren Byers, Floriana Morgillo, and Fortunato Ciardiello
- Subjects
Innate immunity ,STING ,NK cells ,Cetuximab ,Avelumab ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background We recently conducted Cetuximab-AVElumab-Lung (CAVE-Lung), a proof-of-concept, translational and clinical trial, to evaluate the combination of two IgG1 monoclonal antibodies (mAb): avelumab, an anti-PD-L1 drug, and cetuximab, an anti-epidermal growth factor receptor (EGFR) drug, as second- or third-line treatment in non-small cell lung cancer (NSCLC) patients. We have reported clinically relevant anti-tumor activity in 6/16 patients. Clinical benefit was accompanied by Natural Killer (NK) cell-mediated antibody-dependent cell cytotoxicity (ADCC). Among the 6 responding patients, 3 had progressed after initial response to a previous treatment with single agent anti-PD-1, nivolumab or pembrolizumab. Methods We report long-term clinical follow-up and additional findings on the anti-tumor activity and on the immune effects of cetuximab plus avelumab treatment for these 3 patients. Results As of November 30, 2021, 2/3 patients were alive. One patient was still on treatment from 34 months, while the other two patients had progression free survival (PFS) of 15 and 19 months, respectively. Analysis of serially collected peripheral blood mononuclear cells (PBMC) revealed long-term activation of NK cell-mediated ADCC. Comprehensive genomic profile analysis found somatic mutations and germline rare variants in DNA damage response (DDR) genes. Furthermore, by transcriptomic analysis of The Cancer Genome Atlas (TCGA) dataset we found that DDR mutant NSCLC displayed high STING pathway gene expression. In NSCLC patient-derived three-dimensional in vitro spheroid cultures, cetuximab plus avelumab treatment induced additive cancer cell growth inhibition as compared to single agent treatment. This effect was partially blocked by treatment with an anti-CD16 mAb, suggesting a direct involvement of NK cell activation. Furthermore, cetuximab plus avelumab treatment induced 10-, 20-, and 20-fold increase, respectively, in the gene expression of CCL5 and CXCL10, two STING downstream effector cytokines, and of interferon β, as compared to untreated control samples. Conclusions DDR mutations may contribute to DDR-induced STING pathway with sustained innate immunity activation following cetuximab plus avelumab combination in previously treated, PD-1 inhibitor responsive NSCLC patients.
- Published
- 2022
- Full Text
- View/download PDF
39. “Meta-analysis of regenerative endodontics outcomes with antibiotics pastes and calcium hydroxide. The apex of the iceberg”
- Author
-
Báez, Viviana, Corcos, Lorena, Morgillo, Florencia, Imperatrice, Lorena, and Gualtieri, Ariel Félix
- Published
- 2022
- Full Text
- View/download PDF
40. Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy?
- Author
-
Insa, Amelia, Martín-Martorell, Paloma, Di Liello, Raimondo, Fasano, Morena, Martini, Giulia, Napolitano, Stefania, Vicidomini, Giovanni, Cappabianca, Salvatore, Franco, Renato, Morgillo, Floriana, and Della Corte, Carminia Maria
- Published
- 2022
- Full Text
- View/download PDF
41. Understanding the role of the gut microbiome in gastrointestinal cancer: A review
- Author
-
Duygu Ağagündüz, Ermelinda Cocozza, Özge Cemali, Ayşe Derya Bayazıt, Maria Francesca Nanì, Ida Cerqua, Floriana Morgillo, Suna Karadeniz Saygılı, Roberto Berni Canani, Paola Amero, and Raffaele Capasso
- Subjects
microbiome ,gastrointestinal cancer ,non-coding RNAs ,therapeutics ,diagnosis ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Gastrointestinal cancer represents one of the most diagnosed types of cancer. Cancer is a genetic and multifactorial disease, influenced by the host and environmental factors. It has been stated that 20% of cancer is caused by microorganisms such as Helicobacter pylori, hepatitis B and C virus, and human papillomavirus. In addition to these well-known microorganisms associated with cancer, it has been shown differences in the composition of the microbiota between healthy individuals and cancer patients. Some studies have suggested the existence of the selected microorganisms and their metabolites that can promote or inhibit tumorigenesis via some mechanisms. Recent findings have shown that gut microbiome and their metabolites can act as cancer promotors or inhibitors. It has been shown that gastrointestinal cancer can be caused by a dysregulation of the expression of non-coding RNA (ncRNA) through the gut microbiome. This review will summarize the latest reports regarding the relationship among gut microbiome, ncRNAs, and gastrointestinal cancer. The potential applications of diagnosing and cancer treatments will be discussed.
- Published
- 2023
- Full Text
- View/download PDF
42. Sociodemographic Characteristics Associated with Harmful Use of Alcohol Among Economically and Socially Disadvantaged Immigrant Patients in Italy
- Author
-
Di Napoli, Anteo, Morgillo, Teresa, Rossi, Alessandra, Ventura, Martina, Nosotti, Lorenzo, Cavani, Andrea, Costanzo, Gianfranco, Mirisola, Concetta, and Petrelli, Alessio
- Published
- 2020
43. Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers
- Author
-
Lobefaro, Riccardo, Viscardi, Giuseppe, Di Liello, Raimondo, Massa, Giacomo, Iacovino, Maria Lucia, Sparano, Francesca, Della Corte, Carminia Maria, Ferrara, Roberto, Signorelli, Diego, Proto, Claudia, Prelaj, Arsela, Galli, Giulia, De Toma, Alessandro, Brambilla, Marta, Ganzinelli, Monica, Trevisan, Benedetta, Ciardiello, Fortunato, De Braud, Filippo, Morgillo, Floriana, Garassino, Marina Chiara, and Lo Russo, Giuseppe
- Published
- 2021
- Full Text
- View/download PDF
44. Auslegung von Hochleistungssaugmodulen mit integriertem indirektem Ladeluftkühler
- Author
-
Stehlig, Jürgen, Morgillo, Ivano, Handel, Rainer, Quinto, Stefano, and Liebl, Johannes, editor
- Published
- 2020
- Full Text
- View/download PDF
45. Immune-Cell-Derived Exosomes as a Potential Novel Tool to Investigate Immune Responsiveness in SCLC Patients: A Proof-of-Concept Study.
- Author
-
Amato, Luisa, De Rosa, Caterina, De Rosa, Viviana, Heydari Sheikhhossein, Hamid, Ariano, Annalisa, Franco, Paola, Nele, Valeria, Capaldo, Sara, Di Guida, Gaetano, Sepe, Filippo, Di Liello, Alessandra, De Rosa, Giuseppe, Tuccillo, Concetta, Gambardella, Antonio, Ciardiello, Fortunato, Morgillo, Floriana, Tirino, Virginia, Della Corte, Carminia Maria, Iommelli, Francesca, and Vicidomini, Giovanni
- Subjects
IN vitro studies ,EXTRACELLULAR vesicles ,MONONUCLEAR leukocytes ,RESEARCH funding ,IMMUNOTHERAPY ,PILOT projects ,APOPTOSIS ,IMMUNE system ,TUMOR markers ,TREATMENT effectiveness ,CANCER patients ,DESCRIPTIVE statistics ,DNA ,CELLULAR signal transduction ,CANCER chemotherapy ,RNA ,ONE-way analysis of variance ,WESTERN immunoblotting ,SCANNING electron microscopy ,CELL death ,DNA damage ,PROGRAMMED cell death 1 receptors ,LUNG cancer ,COMPARATIVE studies ,DATA analysis software ,CELL survival ,EXOSOMES ,PHENOTYPES - Abstract
Simple Summary: In the era of precision medicine and immunotherapy, the isolation and characterization of exosomes from the peripheral blood mononuclear cells (PBMC-EXs) of SCLC patients may represent a new tool to define responder (BR) from non-responder (NR) patients undergoing chemoimmunotherapy treatment. In this proof-of-concept study, we isolated PBMC-EXs from the peripheral blood of SCLC patients and investigated the potential role of such extracellular vesicles (EVs) in monitoring tumor response to drug stimuli. Interestingly, we found increased exosome levels of c-Myc and Snail along with reduced levels of the immune markers MAVS and STING in NR patients. Also, we showed that PBMC-EXs from BR patients induced an increase in apoptosis and a reduction in the cell viability of SCLC cells compared to PBMC-EXs from NR SCLC patients. Thus, we suggest that PBMC-EXs may represent an innovative strategy to be further explored for the therapy and selection of immune-responsive SCLC patients. Small cell lung cancer (SCLC) is a highly invasive and rapidly proliferating lung tumor subtype. Most patients respond well to a combination of platinum-based chemotherapy and PD-1/PDL-1 inhibitors. Unfortunately, not all patients benefit from this treatment regimen, and few alternative therapies are available. In this scenario, the identification of new biomarkers and differential therapeutic strategies to improve tumor response becomes urgent. Here, we investigated the role of exosomes (EXs) released from the peripheral blood mononuclear cells (PBMCs) of SCLC patients in mediating the functional crosstalk between the immune system and tumors in response to treatments. In this study, we showed that PBMC-EXs from SCLC patients with different responses to chemoimmunotherapy showed different levels of immune (STING and MAVS) and EMT (Snail and c-Myc) markers. We demonstrated that PBMC-EXs derived from best responder (BR) patients were able to induce a significant increase in apoptosis in SCLC cell lines in vitro compared to PBMC-EXs derived from non-responder (NR) SCLC patients. PBMC-EXs were able to affect cell viability and modulate apoptotic markers, DNA damage and the replication stress pathway, as well as the occurrence of EMT. Our work provides proof of concept that PBMC-EXs can be used as a tool to study the crosstalk between cancer cells and immune cells and that PBMC-EXs exhibit an in vitro ability to promote cancer cell death and reduce tumor aggressiveness. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials
- Author
-
Piera Gargiulo, Laura Arenare, Cesare Gridelli, Alessandro Morabito, Fortunato Ciardiello, Vittorio Gebbia, Paolo Maione, Alessia Spagnuolo, Giuliano Palumbo, Giovanna Esposito, Carminia Maria Della Corte, Floriana Morgillo, Gianfranco Mancuso, Raimondo Di Liello, Adriano Gravina, Clorinda Schettino, Massimo Di Maio, Ciro Gallo, Francesco Perrone, and Maria Carmela Piccirillo
- Subjects
Lung cancer ,Chemotherapy-induced neutropenia (CIN) ,Retrospective-prospective design ,Prognostic factors ,Overall survival ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Chemotherapy-induced neutropenia (CIN) has been demonstrated to be a prognostic factor in several cancer conditions. We previously found a significant prognostic value of CIN on overall survival (OS), in a pooled dataset of patients with advanced non-small-cell lung cancer (NSCLC) receiving first line chemotherapy from 1996 to 2001. However, the prognostic role of CIN in NSCLC is still debated. Methods We performed a post hoc analysis pooling data prospectively collected in six randomized phase 3 trials in NSCLC conducted from 2002 to 2016. Patients who never started chemotherapy and those for whom toxicity data were missing were excluded. Neutropenia was categorized on the basis of worst grade during chemotherapy: absent (grade 0), mild (grade 1–2), or severe (grade 3–4). The primary endpoint was OS. Multivariable Cox model was applied for statistical analyses. In the primary analysis, a minimum time (landmark) at 180 days from randomization was applied in order to minimize the time-dependent bias. Results Overall, 1529 patients, who received chemotherapy, were eligible; 572 of them (who received 6 cycles of treatment) represented the landmark population. Severe CIN was reported in 143 (25.0%) patients and mild CIN in 135 (23.6%). At multivariable OS analysis, CIN was significantly predictive of prognosis although its prognostic value was entirely driven by severe CIN (hazard ratio [HR] of death 0.71; 95%CI: 0.53–0.95) while it was not evident with mild CIN (HR 1.21; 95%CI: 0.92–1.58). Consistent results were observed in the out-of-landmark group (including 957 patients), where both severe and mild CIN were significantly associated with a reduced risk of death. Conclusion The pooled analysis of six large trials of NSCLC treatment shows that CIN occurrence is significantly associated with a longer overall survival, particularly in patients developing severe CIN, confirming our previous findings.
- Published
- 2021
- Full Text
- View/download PDF
47. Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis
- Author
-
Christine M. Bestvina, MD, Jennifer G. Whisenant, PhD, Valter Torri, MD, Alessio Cortellini, MD, Heather Wakelee, MD, Solange Peters, MD, PhD, Elisa Roca, MD, PhD, Alessandro De Toma, MD, Fred R. Hirsch, MD, Hirva Mamdani, MD, Balazs Halmos, MD, Oscar Arrieta, MD, Anne-Cecile Metivier, MD, Mary J. Fidler, MD, Jacobo Rogado, MD, Carolyn J. Presley, MD, MHS, Celine Mascaux, MD, Carlo Genova, MD, PhD, Juan Bautista Blaquier, MD, Alfredo Addeo, MD, Giovanna Finocchiaro, MD, Hina Khan, MD, Julien Mazieres, MD, PhD, Floriana Morgillo, MD, PhD, Jair Bar, MD, Avinash Aujayeb, MBBS, Giannis Mountzios, MD, PhD, Vieri Scotti, MD, Federica Grosso, MD, Erica Geraedts, MD, Ardak N. Zhumagaliyeva, MD, PhD, Leora Horn, MD, Marina Chiara Garassino, MD, and Javier Baena, MD
- Subjects
COVID-19 ,Cancer ,Thoracic ,NSCLC ,TERAVOLT ,Registry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Introduction: The Thoracic Centers International coronavirus disease 2019 (COVID-19) Collaboration (TERAVOLT) registry found approximately 30% mortality in patients with thoracic malignancies during the initial COVID-19 surges. Data from South Africa suggested a decrease in severity and mortality with the Omicron wave. Our objective was to assess mortality of patients with thoracic malignancies with the Omicron-predominant wave and evaluate efficacy of vaccination. Methods: A prospective, multicenter observational study was conducted. A total of 28 institutions contributed data from January 14, 2022, to February 4, 2022. Inclusion criteria were any thoracic cancer and a COVID-19 diagnosis on or after November 1, 2021. End points included mortality, hospitalization, symptomatic COVID-19 infection, asymptomatic COVID-19 infection, and delay in cancer therapy. Analysis was done through contingency tables and a multivariable logistic model. Results: We enrolled a total of 346 patients. Median age was 65 years, 52.3% were female, 74.2% were current or former smokers, 86% had NSCLC, 72% had stage IV at time of COVID-19 diagnosis, and 66% were receiving cancer therapy. Variant was unknown for 70%; for those known, Omicron represented 82%. Overall mortality was 3.2%. Using multivariate analysis, COVID-19 vaccination with booster compared with no vaccination had a protective effect on hospitalization or death (OR = 0.30, confidence interval: 0.15–0.57, p = 0.0003), whereas vaccination without booster did not (OR = 0.64, confidence interval: 0.33–1.24, p = 0.1864). Cancer care was delayed in 56.4% of the patients. Conclusions: TERAVOLT found reduced patient mortality with the most recent COVID-19 surge. COVID-19 vaccination with booster improved outcomes of hospitalization or death. Delays in cancer therapy remain an issue, which has the potential to worsen cancer-related mortality.
- Published
- 2022
- Full Text
- View/download PDF
48. AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer
- Author
-
Cardone, Claudia, Blauensteiner, Bernadette, Moreno-Viedma, Veronica, Martini, Giulia, Simeon, Vittorio, Vitiello, Pietro P., Ciardiello, Davide, Belli, Valentina, Matrone, Nunzia, Troiani, Teresa, Morgillo, Floriana, Zito Marino, Federica, Dentice, Monica, Nappi, Annarita, Boccaccino, Alessandra, Antoniotti, Carlotta, Cremolini, Chiara, Pietrantonio, Filippo, Prager, Gerald W., Normanno, Nicola, Maiello, Evaristo, Argiles, Guillem, Elez, Elena, Signoriello, Giuseppe, Franco, Renato, Falcone, Alfredo, Tabernero, Josep, Sibilia, Maria, Ciardiello, Fortunato, and Martinelli, Erika
- Published
- 2020
- Full Text
- View/download PDF
49. Immunotherapy as first-line treatment in locally advanced/metastatic and previously untreated squamous cell lung cancer: which advances?
- Author
-
Giorgiano, Noemi Maria, primary, Pentimalli, Francesca, additional, Natale, Giovanni, additional, Corte, Carminia Maria Della, additional, Morgillo, Floriana, additional, and Fiorelli, Alfonso, additional
- Published
- 2024
- Full Text
- View/download PDF
50. New perspectives on inoperable early-stage lung cancer management: Clinicians, physicists, and biologists unveil strategies and insights
- Author
-
Buono, Mauro, primary, Russo, Gianluca, additional, Nardone, Valerio, additional, Della Corte, Carminia Maria, additional, Natale, Giovanni, additional, Rubini, Dino, additional, Palumbo, Lucia, additional, Scimone, Claudia, additional, Ciani, Giovanni, additional, D'Onofrio, Ida, additional, Grassi, Roberta, additional, Fiorelli, Alfonso, additional, Morgillo, Floriana, additional, Reginelli, Alfonso, additional, Troncone, Giancarlo, additional, and Cappabianca, Salvatore, additional
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.